Dr. Conlin on the Implications of the HER2-Low Subset in Breast Cancer

Alison K. Conlin, MD, medical oncology, Providence Cancer Institute Franz Clinic, discusses the inception of the HER2-low breast cancer treatment landscape.

Movement in the breast cancer treatment landscape has been underscored by the development and approval of new agents and indications, Conlin explains. Recent data from clinical trials have identified HER2-low as a recognizable new subset of patients in the breast cancer space, Conlin adds.

With the treatment landscape within breast cancer continuing to grow, clinical research and enrolling patients to clinical trials will be vital to best identify optimal treatment strategies for different groups of patients, Conlin concludes.